Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate whether antifungal prophylaxis with isavuconazole
can reduce the incidence of SARS-CoV-2-associated invasive aspergillosis in patients in the
ICU (intensive care unit) with severe COVID-19 infection.
The investigators will perform an interventional, double-blinded, randomized-controlled,
multi-center study in patients with severe COVID-19 infection admitted to the ICU. Patients
will be randomized to the isavuconazole prophylaxis plus standard of care (SOC) group or the
placebo plus SOC group. Participants will receive isavuconazole or placebo for up to 28 days
or until discharge from the hospital (whichever occurs first).